As of Friday close, Hims & Hers Health Inc.’s (NYSE:HIMS) stock was up $0.07, moving up 1.08 percent to $6.55. The average number of shares traded per day over the past five days has been 1,897,720 shares. 4 times new highs have been achieved over the past 5 days, with a $0.36 gain in that time frame. In the last twenty days, the average volume was 1,698,000, while in the previous 50 days, it was 2,142,140.
Since last month, HIMS stock rose 16.76%. Shares of the company fell to $4.96 on 07/06/22, the lowest level in the past month. A 52-week high of $9.35 was reached on 01/04/22 after having rallying from a 52-week low of $2.72. Since the beginning of this year, HIMS’s stock price has dropped by 0.00%, and marked a new high 2 times. However, the stock has declined by -29.95% since its 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Hims & Hers Health Inc. (HIMS) last reported insider trading activity 32 days ago on Jul 05. Becklund Irene, the PAO of the company, disposed of 19,331 shares for $5.00 on Jul 05. It resulted in a $96,655 divestment by the insider. O’Keefe Lynne Chou sold 10,045 shares at an average price of $4.35 on Jun 21. The insider now owns 0 shares following the transaction. On Jun 14, Director Maltz Jules A. bought 75,000 shares at $3.66 apiece. The transaction was valued at $274,494.
In the three months ended March 30, Hims & Hers Health Inc.’s quick ratio stood at 4.50, while its current ratio was 4.80, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 74.50% percent. In the year ended March 30, operating margins totaled -26.00%. Based on annual data, HIMS earned $204.49 million in gross profit and brought in $271.88 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -33.50%. Return on equity (ROE) for the past 12 months was -22.10%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. HIMS’s revenue rose 48.37% to $84.7 million during the quarter, while net income inched up to $101.31 million. While analysts expected Hims & Hers Health Inc. to report -$0.07 quarterly earnings, the actual figure was -$0.08 per share, beating the consensus estimate by -14.30%. During the quarter, the company generated -$14.21 million in EBITDA. The liabilities of Hims & Hers Health Inc. were 54.32 million at the end of its most recent quarter ended March 30, and its total debt was $5.15 million. The value of shareholders’ equity is $206.06 million.
This quick technical analysis looks at Hims & Hers Health Inc.’s (HIMS) price momentum. With a historical volatility rate of 34.69%, the RSI 9-day stood at 75.36% on 05 August.
With respect to its five-day moving average, the current Hims & Hers Health Inc. price is up by +5.82% percent or $0.36. At present, HIMS shares trade +16.96% above its 20-day simple moving average and +67.95% percent above its 100-day simple moving average. However, the stock is currently trading approximately +91.52% above its SMA50 and -20.70% below its SMA200.
Stochastic coefficient K was 85.80% and Stochastic coefficient D was 88.21%, while ATR was 0.35. Given the Stochastic reading of 87.39% for the 14-day period, the RSI (14) reading has been calculated as 72.92%. As of today, the MACD Oscillator reading stands at 0.31, while the 14-day reading stands at 0.40.
SVB Leerink launched its rating on Hims & Hers Health Inc. (NYSE: HIMS) to an Underperform in a note to investors on July 15, 2022. Hims & Hers Health Inc. (HIMS) has been rated Overweight by analysts. According to 1 brokerage firm, HIMS is a sell, and 3 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Hims & Hers Health Inc. stock as buy, with 4 recommending it as overweight.
With a median target price of $6.25, the current consensus forecast for the stock is $4.00 – $10.00. Based on these forecasts, analysts predict Hims & Hers Health Inc. (HIMS) will achieve an average price target of $6.31.